Peptide Tools to Study Monkeypox Virus



About Monkeypox Virus

Monkeypox virus (Orthopoxvirus simiae) belongs to the family of Poxviridae, which can cause a zoonotic disease commonly referred to Monkeypox. 83 species belong to this family of these double- stranded DNA viruses including the orthopox subfamily with

  • Smallpox virus (Variola)
  • Vaccinia virus
  • Cowpox virus
  • Rabbitpox virus
  • Monkeypox virus
 Though rodents appear to be the primary reservoir for the monkeypox virus, primates can carry the virus and can promote its transmission to humans. Monkeypox infection primarily occurs in central and west Africa and was first identified in a human in 1970. The recent outbreak in several non- endemic countries (with many cases in Europe) has sparked a new interest in the epidemiology, sources and mechanism of infection, transmission patterns and cross-reactivity of monkeypox virus. 

Of note, the common chickenpox virus (varicella zoster virus) is a herpesvirus and does not belong to the poxviruses. 


Cross-immunity within the Orthopox subfamily 

Vaccination against smallpox seems to be quite effective (approx. 85%) in preventing monkeypox as shown in several observational studies. This could be because many of the viral proteins show great levels of homology within different orthopoxviridae as shown in belows table.


Uniprot ID Protein name PepMix Product Code Homology (%)*
O57206 IMV heparin binding surface protein (MVA093L) PM-MVA-093L 96.6
O57211 Cell surface-binding protein (MVA105L) PM-MVA-105L 97
O57196 Putative 49.8k protein (MVA 074R) PM-MVA-074R 98.8
P68598 Host range protein 2 (MVA018L) PM-MVA-018L 99.3
O57223 Major core protein P4a (MVA 121L) PM-MVA-121L 98.3
P07614 Protein L3 PM-VACV-L3L 97.4
O57265 Putative 21.7k protein (MVA189R) PM-MVA-189R 63.5

* defined as the percentage of residues with a positive BLOSUM50 score (gap is score -5) in a comparison of aligned sequences.

 Table 1: Homology of different vaccinia antigens that are represented in JPT’s proprietary PepMix peptide pools with the respective monkeypox antigens.




JPT's Peptide Tools to Study Monkeypox Virus

Cellular Immune Response Profiling

JPT offers custom peptide synthesis, peptide libraries, microarrays and pools for research and development of vaccines, diagnostics and therapy. We provide knowledgeable support, high quality, flexible and innovative formats combined with expert expertise to bring forward your research project.

 PepMix™ Peptide Pools

  • efficient for antigen-specific stimulation in T cell assays such as ELISPOT and flow cytometry
  • highest quality and batch-to-batch consistency, whole production ISO 9001 certified
  • PepMix Pan-Poxviridae Select: 127 immunodominant peptide epitopes combining all major antigens of Monkeypox virus (MPXV), Smallpox virus (VARV), Vaccinia virus (VACV), Variola virus (VARV)
  • PepMix peptide pools for various Vaccinia virus antigens: e.g. Protein L3, IMV heparin binding surface protein, cell surface-binding protein and more
  • Custom PepMix™ Peptide Pools tailored for your specific needs!

PepTrack™ Peptide Libraries

  • T-cell assays * High-throughput T-cell epitope discovery 
  • Monitoring of cellular immune response

Custom Peptide Synthesis 

We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide. If you would like to order a quality peptide synthesis using regulated processes, choose JPT!

Humoral Immune Response Profiling

PepStar™ Peptide Microarrays

Peptide ELISA 
In addition to high-content peptide microarrays, JPT offers the development of peptide based enzyme-linked immunosorbent assays (ELISA). This common analytical and highly sensitive immunological assay is well established for proteins but requires detailed experimental expertise for peptides.

Clinical Peptides

Clinical Peptides

Production of JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus is regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development.
Loading...

References

References

  • Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study
    Agrati et al., The Lancet (2022)
  • Safety and Immunogenicity of a Modified Vaccinia Virus Ankara Vector Vaccine Candidate for Middle East Respiratory Syndrome: an Open-Label, Phase 1 Trial 
    Koch et al, Lancet (2020)
  • A Vaccine Based on Recombinant Modified Vaccinia Ankara Containing the Nucleoprotein from Lassa Virus Protects Against Disease Progression in a Guinea Pig Model 
    Kennedy et al, Vaccine (2019)
  • Characterization of the Immune Response Elicited by the Vaccinia Virus L3 Protein Delivered as Naked DNA
    Ramìres et al,  Vaccine (2018) 
Application Notes
Loading...

Check our list of products, click and go.

Get a quote